Abstract
The WTO Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs Agreement) has historically been interpreted as recognising the difficulties associated with patent protection for pharmaceuticals needed to protect public health and welfare. Where a sovereign state's law or policy allows for use of the subject matter of a patent without the authorisation of the rights holder, such use may only be permitted if, prior to such use, the proposed user has made efforts to obtain authorisation from the rights holder on reasonable commercial terms. Many countries, however, are beginning to challenge such 'negotiated' use, opting instead to institute unilateral patent use policies. Summarised here is a compulsory license policy for patented pharmaceuticals recently enacted by the Government of Thailand, supported by their ten point argument which could serve as a template for less restrictive licensing policies needed by developing countries around the world.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Intellectual Property Management
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
